Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...
Fourteen years after it launched Lexiscan in the U.S., Astellas is trying to wring the last bit of market exclusivity it can get out of the scanning agent. In federal court last week in Delaware, ...
Lexiscan is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan should not be administered to patients with second- or third-degree AV ...
Point LomaPoint Loma — A new approach to reducing sickle cell anemia’s painful attacks has entered Phase II clinical trials. The drug, Lexiscan, is already approved for diagnosing heart disease.
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Dr. Reddy's is offering ...
It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the ...
PALO ALTO, Calif., June 24 -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that in conjunction with the commercial launch of Lexiscan(TM) by Astellas Pharma US, Inc., CV Therapeutics has ...
DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. May 13, ...
Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac nuclear stress tests of patients with signs or ...
Lexiscan Clinical Trials In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results